Intellectual Property


The first patent protects 8-hydroxyquinolines, as new racemic compounds and their therapeutic application (priority date: May 2011; WO2011148208 A1), and was granted world-wide. A new patent on synthesis and application of enantiomer pure candidates, including Q134R was submitted in 2015 (WO2016162706 A1), and was granted in several countries and is currently under review in others. Patents enable widespread coverage and long-term exploitation of the IP.


Our first patent titled „8-hydroxy-quinoline derivatives” protects 8-hydroxyquinolines as new racemic compounds and their therapeutic applications (priority date: May 2011; patent application number: WO2011148208 A1). This patent was granted in USA, Europe, Canada, Brazil, India, Eurasia, Australia, China, Indonesia, Japan, South-Korea, Mexico, and New-Zealand.

Summary: The compounds of the general formula and their pharmaceutically acceptable salts can be used in the medicine mainly for the treatment of diseases associated with neurological and/or oxidative stress, which are selected from the following: ischemia, reperfusion injury, cardiovascular disorders, neurodegenerative disorders (including especially Alzheimer’s disease and Huntington’s disease), trauma, neuropsychiatric diseases (including especially depression and anxiety disorders), and liver, kidney and lung injuries.

8-hydroxy-quinoline derivatives

The second patent titled „Enantiomers of 8-Hydroxy Quinoline derivatives and the synthesis thereof” on the synthesis and application of the enantiopure candidates, including Q134R was submitted in 2015 (patent application number: WO2016162706 A1), it is already partly granted in the USA and Indonesia, and is under granting process in Europe, Canada, Eurasia, Australia, China, Japan, South-Korea, Mexico, New-Zealand, Brazil, and India.

Summary: The novel medicinal and/or pharmaceutical compositions empowers these enantiomers to be used preferably as cytoprotective, neuroprotective, cardioprotective, anxiolytic and antidepressant agents for the treatment of neuropsychiatric and neurologic diseases and diseases in connections with transplantations and with ischemia and reperfusion injuries, further the inhibition of organ and skin graft rejection. According to our studies the R-enantiomer has either sole or high biological effect in some cases.

New Enantiomers of 8-Hydroxyquinoline Derivatives and the Synthesis Thereof